Gul O Oz, Sisman P, Cander S, Sarandol E, Ersoy C, Erturk E
Uludag University Medical School, Department of Endocrinology and Metabolism, Bursa, Turkey.
Medicana Hospital, Endocrinology and Metabolism Clinic, Bursa, Turkey.
Acta Endocrinol (Buchar). 2022 Jan-Mar;18(1):35-39. doi: 10.4183/aeb.2022.35.
Insulin resistance has been detected in a majority of patients with polycystic ovary syndrome (PCOS). Elevated neprilysin levels are associated with insulin resistance.
The present study aims to investigate plasma neprilysin and its relationship with endocrine and metabolic characteristics in patients with PCOS.
Thirty-five premenopausal PCOS patients and 35 healthy volunteers of similar age were included in the study. Demographic characteristics, biochemical and hormonal findings and also plasma neprilysin levels were determined in these patients and healthy controls.
In our study, HOMA-IR values were significantly higher in PCOS patients (3.3 ± 1.8) compared with the controls [(1.6 ± 1), p<0.01]. Plasma neprilysin levels were significantly higher in the PCOS group compared to the control group (1502.1 ± 1641.2 . 764.6 ± 562.6 pg/mL). There was no difference in plasma neprilysin levels when PCOS patients were classified as overweight-obesity (BMI≥25kg/m) or non-obesity (BMI<25kg/m).
Our findings revealed significantly higher levels for plasma neprilysin and HOMA-IR values in PCOS patients when compared to controls. No significant differences were noted between obese PCOS patients and non-obese PCOS patients in terms of plasma neprilysin levels.
在大多数多囊卵巢综合征（PCOS）患者中已检测到胰岛素抵抗。中性内肽酶水平升高与胰岛素抵抗相关。
本研究旨在调查PCOS患者的血浆中性内肽酶及其与内分泌和代谢特征的关系。
本研究纳入了35名绝经前PCOS患者和35名年龄相仿的健康志愿者。测定了这些患者和健康对照者的人口统计学特征、生化和激素检查结果以及血浆中性内肽酶水平。
在我们的研究中，PCOS患者的HOMA-IR值（3.3±1.8）显著高于对照组（1.6±1，p<0.01）。PCOS组的血浆中性内肽酶水平显著高于对照组（1502.1±1641.2对764.6±562.6 pg/mL）。当PCOS患者分为超重肥胖（BMI≥25kg/m）或非肥胖（BMI<25kg/m）时，血浆中性内肽酶水平无差异。
我们的研究结果显示，与对照组相比，PCOS患者的血浆中性内肽酶水平和HOMA-IR值显著更高。在血浆中性内肽酶水平方面，肥胖PCOS患者和非肥胖PCOS患者之间未观察到显著差异。
